RECRUITING Phase 2 ClinicalTrials.gov

Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism

Sponsor: National Cancer Institute (NCI) • ClinicalTrials.gov ID: NCT06246357

Registry updated: 2026-10-22

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

Background: The adrenal glands are 2 small organs that sit on top of each kidney. They release hormones; these are chemicals that control how the body works. Tumors on or outside the adrenal glands are called functional if they release hormones; they are called nonfunctional if they do not. Doctors who treat adrenal tumors need to know which type a person has. Researchers want to find better ways to learn whether an adrenal tumor is functional. Objective: To see if a new radioactive tracer (\[68Ga\]Ga-PentixaFor) can make it easier to identify functional adrenal tumors with positron emission tomography (PET) scans. Eligibility: People aged 18 years and older with 1 or more adrenal tumors. They must have increased levels of the hormones aldosterone or cortisol. They must also be enrolled in at least 1 other related NIH study (protocols 19-DK-0066, 18-CH-0031, or 09-C-0242). Design: Participants will be screened. They may have imaging scans. Their ability to perform normal activities will be reviewed. Participants will have one PET scan with the study tracer. The tracer will be given through a tube attached to a needle inserted into a vein. Participants will receive the tracer 1 hour before the scan. They will lie still on a bed while a machine captures images of the inside of their body. The scan will take 45 to 90 minutes. Participants heart rate, blood pressure, and rate of breathing will be checked before, during, and after the scan. Participants will have a follow-up visit 3 days after their scan. This visit can be by phone, email, or in person.

Interventions

[68Ga]Ga-PentixaFor (Drug)
\[68Ga\]Ga-PentixaFor will be injected intravenously approximately 60 minutes prior to scanning at a dose of 150 +/- 50 MBq (4 mCi +/- 1.4).

Eligibility criteria

* INCLUSION CRITERIA: * Must have any of the following: * one or more adrenal masses on CT and/or MRI and biochemical evidence of excess aldosterone OR --ACTH-independent hypercortisolism, with or without adrenal masses on CT and/or MRI OR * history of ACTH-dependent hypercortisolism (with or without adrenal enlargement) * Co-enrollment in 19-DK-0066, 09-C-0242, 18-CH-0031 or a similar NIH trial. * Age \>=18 years. * ECOG performance status \<= 2. * Women of child-bearing potential (WOCBP) and men must agree to use an effective contraception (barrier, hormonal, intrauterine device \[IUD\], surgical sterilization, abstinence) for two weeks prior to \[68Ga\]Ga-PentixaFor scan and for one week after the \[68Ga\]Ga-PentixaFor scan. * Breastfeeding should be discontinued for one week after the \[68Ga\]Ga-PentixaFor scan. * Men must agree not to donate sperm for one week after the \[68Ga\]Ga-PentixaFor scan. * Participants must be able to understand and willing to sign a written informed consent document. EXCLUSION CRITERIA: * Positive beta-human chorionic gonadotropin (beta-HCG) serum or urine pregnancy test performed in females of childbearing potential at screening. * Uncontrolled intercurrent illness or social situations based on the review of medical history that would limit compliance with study requirements. * Contraindications to having an MRI and CT.

Conditions

Hyperaldosteronism Hypercortisolism Cushing s Syndrome

Locations

National Institutes of Health Clinical Center — Bethesda, Maryland, United States

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment